SpringWorks Gets HC Wainwright Bullish Pitch
- HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc nirogacestat clinical profile for desmoid tumors after the R&D day held last week.
- As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80% and 87% of medical oncologists believe that nirogacestat compares favorably to Bayer AG's
BAYRY
Nexavar (sorafenib) and that they are willing to switch current patients to nirogacestat, respectively. - The analysts forecast nirogacestat achieving a peak penetration rate of 25% and 65% in the front-line and second-line desmoid tumor setting, respectively.
- They anticipate submitting an FDA marketing application for nirogacestat in desmoid tumors in 2H22.
- Moving to SpringWorks' earlier stage pipeline, the management also provided initial results for mirdametinib combined with lifirafenib, BeiGene Ltd's
- Most clinical responses came from patients with low-grade serous ovarian carcinoma with MAPK activating mutations, with a 73% ORR and a 100% disease control rate.
- HC Wainwright reiterates a Buy rating on SpringWorks Therapeutics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.